Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease

[1]  P. Rutgeerts,et al.  Post Hoc Analysis , 2022, The SAGE Encyclopedia of Research Design.

[2]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[3]  James R. Powell,et al.  Should Baseline Hemoglobin A1c or Dose of SGLT‐2i Guide Treatment With SGLT‐2i Versus DPP‐4i in People With Type 2 Diabetes? A Meta‐Analysis and Systematic Review , 2020, Journal of clinical pharmacology.

[4]  Xiaoxia Peng,et al.  A New Approach Is Needed to Evaluate 24‐Hour Urinary Sodium Excretion Using Spot Urines: A Validation Study in a Chinese Child Population , 2019, Journal of the American Heart Association.

[5]  B. Zinman,et al.  Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. , 2019, Circulation.

[6]  R. Sofat,et al.  24-hour vs Spot Urinary Sodium and Potassium Measurements in Adult Hypertensive patients; A Cohort Validation Study. , 2019, American journal of hypertension.

[7]  Y. Terauchi,et al.  Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study) , 2019, Cardiovascular Diabetology.

[8]  Deepak L. Bhatt,et al.  Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. , 2019, The lancet. Diabetes & endocrinology.

[9]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[10]  N. Cook,et al.  Formulas to Estimate Dietary Sodium Intake From Spot Urine Alter Sodium-Mortality Relationship. , 2019, Hypertension.

[11]  K. Kaku,et al.  Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status , 2019, Diabetes, obesity & metabolism.

[12]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[13]  N. Stefan,et al.  Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy , 2019, Cardiovascular Diabetology.

[14]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[15]  Michael S. Kelly,et al.  Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease , 2018, Postgraduate medicine.

[16]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[17]  T. Sugase,et al.  Effects of the sodium‐glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan , 2019, Nephrology.

[18]  K. Kario,et al.  24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study. , 2018, Circulation.

[19]  D. Cherney,et al.  Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. , 2018, American journal of physiology. Renal physiology.

[20]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[21]  Y. Seino,et al.  Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials , 2018, Journal of diabetes investigation.

[22]  G. Laverman,et al.  Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers , 2018, Diabetes, obesity & metabolism.

[23]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[24]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[25]  L. Ghiadoni,et al.  Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study , 2017, Cardiovascular Diabetology.

[26]  H. Uchino,et al.  Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study , 2017, Cardiovascular Diabetology.

[27]  K. Kario,et al.  Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　- The NOCTURNE Study. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[28]  L. Dell’Italia,et al.  Novel Paradigms of Salt and Hypertension. , 2017, Journal of the American Society of Nephrology : JASN.

[29]  Dave L Dixon,et al.  Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis , 2017, Journal of the American Heart Association.

[30]  M. Miyata,et al.  Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes , 2017, BMC Pharmacology and Toxicology.

[31]  H. Heerspink,et al.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. , 2017, Journal of the American Society of Nephrology : JASN.

[32]  R. Townsend,et al.  Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis , 2017, Cardiovascular Diabetology.

[33]  T. Ohkubo,et al.  Associations of socioeconomic status with prevalence, awareness, treatment, and control of hypertension in a general Japanese population: NIPPON DATA2010 , 2017, Journal of hypertension.

[34]  V. Vallon,et al.  Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.

[35]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[36]  N. Markandu,et al.  Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial , 2016, Hypertension.

[37]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[38]  Merlin C. Thomas,et al.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease , 2016, Nature Reviews Nephrology.

[39]  S. Ito,et al.  Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study , 2015, Journal of clinical medicine research.

[40]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[41]  D. Malta,et al.  Validation study of the Tanaka and Kawasaki equations to estimate the daily sodium excretion by a spot urine sample. , 2015, Revista brasileira de epidemiologia = Brazilian journal of epidemiology.

[42]  C. Cannon,et al.  Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[43]  Hakuo Takahashi,et al.  Validation of two automatic devices: Omron HEM-7252G-HP and Omron HEM-7251G for self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010 , 2015, Blood pressure monitoring.

[44]  堀川 千嘉.  Dietary Sodium Intake and Incidence of Diabetes Complications in Japanese Patients with Type 2 Diabetes: Analysis of the Japan Diabetes Complications Study (JDCS) , 2015 .

[45]  A. Girardi,et al.  Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. , 2014, Journal of the American Society of Nephrology : JASN.

[46]  Majid Ezzati,et al.  Global sodium consumption and death from cardiovascular causes. , 2014, The New England journal of medicine.

[47]  Y. Ohashi,et al.  Dietary sodium intake and incidence of diabetes complications in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS). , 2014, The Journal of clinical endocrinology and metabolism.

[48]  R. Minutolo,et al.  Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  K. Sung,et al.  Estimation of 24-Hour Urinary Sodium Excretion Using Spot Urine Samples , 2014, Nutrients.

[50]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[51]  Peilin Shi,et al.  Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide , 2013, BMJ Open.

[52]  D. de Zeeuw,et al.  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[53]  H. Parving,et al.  Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. , 2012, Kidney international.

[54]  T. Hosoya,et al.  Estimation of salt intake from spot urine samples in patients with chronic kidney disease , 2012, BMC Nephrology.

[55]  V. Vallon,et al.  Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. , 2012, Annual review of physiology.

[56]  Massimo Volpe,et al.  Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. , 2011, Archives of internal medicine.

[57]  G. Moneta.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .

[58]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[59]  G. MacGregor,et al.  A comprehensive review on salt and health and current experience of worldwide salt reduction programmes , 2009, Journal of Human Hypertension.

[60]  M. Ravera,et al.  Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. , 2005, Journal of the American Society of Nephrology : JASN.

[61]  Kazuhiko Ishikawa,et al.  Salt sensitivity of Japanese from the viewpoint of gene polymorphism. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[62]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[63]  H. Ueshima,et al.  A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen , 2002, Journal of Human Hypertension.

[64]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. , 2001, The New England journal of medicine.

[65]  N. Okada,et al.  Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. , 2001, Diabetes care.

[66]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[67]  Orton,et al.  EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .

[68]  T. Uzu,et al.  Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. , 1997, Circulation.

[69]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[70]  G. Jerums,et al.  Glomerular Filtration Rate in Streptozocin-Induced Diabetic Rats: Role of Exchangeable Sodium, Vasoactive Hormones, and Insulin Therapy , 1990, Diabetes.